# Psikotrop ilaç kullanan hastalarda potansiyel olarak anlamlı ilaç etkileşimlerinin değerlendirilmesi: gerçek yaşam verisine dayalı retrospektif çalışma (Assessment of potentially significant drug interactions in patients taking psychotropic medications: a retrospective study based on real-world data) - URL: https://alisanburak.com/en/wcp-2026-posterler/ev1139 - Language: en - Last updated: not specified - Page title: Psikotrop ilaç kullanan hastalarda potansiyel olarak anlamlı ilaç etkileşimlerinin değerlendirilmesi: gerçek yaşam verisine dayalı retrospektif çalışma (Assessment of potentially significant drug interactions in patients taking psychotropic medications: a retrospective study based on real-world data) | WCP 2026 Summary > At least one potential drug interaction was identified in more than half of outpatients taking psychotropic medications, and the vast majority of these were mo… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev1139) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV1139 E-PosterPsychopharmacologyRetrospective chart review # Psikotrop ilaç kullanan hastalarda potansiyel olarak anlamlı ilaç etkileşimlerinin değerlendirilmesi: gerçek yaşam verisine dayalı retrospektif çalışma (Assessment of potentially significant drug interactions in patients taking psychotropic medications: a retrospective study based on real-world data) EVALUATION OF POTENTIALLY SIGNIFICANT DRUG-DRUG INTERACTIONS AMONG PATIENTS RECEIVING PSYCHOTROPIC MEDICATIONS: A REAL-WORLD RETROSPECTIVE STUDY Presenter: Shatha Alqam Country: Qatar Institution: Hamad Medical Corporation, Mental Health Services, Pharmacy Department At least one potential drug interaction was identified in more than half of outpatients taking psychotropic medications, and the vast majority of these were moderate interactions (Category C) requiring therapy monitoring. The aim of the study was to identify significant drug–drug interactions (DDIs) and report their prevalence among patients receiving psychotropic medications at the outpatient mental health clinics of the Enaya Continuing Care Compound (ECC2) in Qatar. The method involved a retrospective chart review of patients who obtained medications from the ECC2 pharmacy between March 1, 2022, and May 2022 and were taking at least one psychotropic medication; interactions were checked using Lexicomp Interact, and descriptive statistical analyses were performed using SPSS (IRB no. MRC-01-22-773). No interactions were identified in 49% of the 1,586 records reviewed, while at least one DDI was found in the remaining 807 patients (51%). These 807 patients had a mean age of 43.86 years (standard deviation 18.02), with 38–47 years being the most common age range (23.3%); approximately 44% had no comorbidities apart from their psychiatric condition, while 17% had at least one medical condition, and the most common diagnoses were depression (22.2%) and schizophrenia (21.9%). Patients were taking an average of 4.69±3.36 medications, of which 2.23±0.96 were psychotropic medications; the mean number of potential interactions per patient was 4.46±5.64, and the total number of potential interactions identified was 2,543. Most interactions were Category C, requiring therapy monitoring (86%, n=2,192), followed by Category D, requiring regimen modification (7.8%, n=200), and Category X, for which the combination should be avoided (1%, n=15). Category X interactions primarily involved the risk of QTc prolongation and torsades de pointes (quetiapine with sulpiride in 5 cases; combinations of flupentixol, quetiapine, and chlorpromazine; quetiapine with methadone), anticholinergic toxicity (fluphenazine or nortriptyline with ipratropium), reduced antipsychotic efficacy (olanzapine or paliperidone with cabergoline), and increased central nervous system depression (fluphenazine or paliperidone with orphenadrine). The authors state that the findings highlight pharmacists’ role in monitoring interactions, but that the retrospective design did not allow assessment of the clinical significance of the interactions or patient outcomes. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1354) How to cite this study APA 7: Alqam, S., et al. (2026, September 23-26). Evaluation of potentially significant drug-drug interactions among patients receiving psychotropic medications: a real-world retrospective study [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1354 Vancouver: Alqam S, et al. Evaluation of potentially significant drug-drug interactions among patients receiving psychotropic medications: a real-world retrospective study [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1354 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev1139 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim